Durvalumab Immunotherapy Nursing management of immune-related adverse events during the journey of patients with stage III non-small cell lung cancer

被引：3

作者：

Davies, Marianne ^{[1
,2
,3
]}

Duffield, Emily ^{[2
]}

机构：

[1] Yale Comprehens Canc Ctr, Dept Med Oncol, New Haven, CT 06510 USA

[2] Yale New Haven Hosp, Smilow Canc Hosp, Dept Nursing, 20 York St, New Haven, CT 06504 USA

[3] Yale Sch Nursing, New Haven, CT 06536 USA

来源：

CLINICAL JOURNAL OF ONCOLOGY NURSING | 2020年 / 24卷 / 03期

关键词：

durvalumab; immunotherapy; immune checkpoint inhibitors; NSCLC; nurse; CHECKPOINT INHIBITORS; OPEN-LABEL; DOCETAXEL; PEMBROLIZUMAB; NIVOLUMAB; THERAPY;

D O I：

10.1188/20.CJON.277-283

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BACKGROUND: When resection is not an option, platinum-based chemoradiotherapy (CRT) has been the historic standard of care in non-small cell lung cancer (NSCLC). Prognosis remains poor with CRT alone. Durvalumab has shown significant improvement (versus placebo) in progression-free and overall survival in patients with unresectable stage III NSCLC without progression following CRT. OBJECTIVE:This article aims to provide an overview of the efficacy and safety outcomes with durvalumab in patients with stage III NSCLC and identify management strategies for potential adverse events (AEs). METHODS: A review of published literature and guidelines was performed to evaluate durvalumab clinical outcomes and AE management strategies. FINDINGS: Durvalumab has established efficacy in patients with unresectable stage III NSCLC and is now the standard of care following CRT. Nurses need to be trained to recognize potential immune-related AEs in patients treated with immune checkpoint inhibitors.

引用

页码：277 / +

页数：8

共 33 条

[1]

[Amin MB. AJCC. AJCC.], 2017, AJCC Cancer Staging Manual, V8th, P431, DOI DOI 10.1007/978-3-319-40618-3

[2] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[3] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[4] Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer [J].

Arbour, Kathryn C. ;

Mezquita, Laura ;

Long, Niamh ;

Rizvi, Hira ;

Auclin, Edouard ;

Ni, Andy ;

Martinez-Bernal, Gala ;

Ferrara, Roberto ;

Lai, W. Victoria ;

Hendriks, Lizza E. L. ;

Sabari, Joshua K. ;

Caramella, Caroline ;

Plodkowski, Andrew J. ;

Halpenny, Darragh ;

Chaft, Jamie E. ;

Planchard, David ;

Riely, Gregory J. ;

Besse, Benjamin ;

Hellmann, Matthew D. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) :2872-+

[5] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[6] The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) [J].

Brahmer, Julie R. ;

Govindan, Ramaswamy ;

Anders, Robert A. ;

Antonia, Scott J. ;

Sagorsky, Sarah ;

Davies, Marianne J. ;

Dubinett, Steven M. ;

Ferris, Andrea ;

Gandhi, Leena ;

Garon, Edward B. ;

Hellmann, Matthew D. ;

Hirsch, Fred R. ;

Malik, Shakuntala ;

Neal, Joel W. ;

Papadimitrakopoulou, Vassiliki A. ;

Rimm, David L. ;

Schwartz, Lawrence H. ;

Sepesi, Boris ;

Yeap, Beow Yong ;

Rizvi, Naiyer A. ;

Herbst, Roy S. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6

[7] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].

Brahmer, Julie R. ;

Lacchetti, Christina ;

Schneider, Bryan J. ;

Atkins, Michael B. ;

Brassil, Kelly J. ;

Caterino, Jeffrey M. ;

Chau, Ian ;

Ernstoff, Marc S. ;

Gardner, Jennifer M. ;

Ginex, Pamela ;

Hallmeyer, Sigrun ;

Chakrabarty, Jennifer Holter ;

Leighl, Natasha B. ;

Mammen, Jennifer S. ;

McDermott, David F. ;

Naing, Aung ;

Nastoupil, Loretta J. ;

Phillips, Tanyanika ;

Porter, Laura D. ;

Puzanov, Igor ;

Reichner, Cristina A. ;

Santomasso, Bianca D. ;

Seigel, Carole ;

Spira, Alexander ;

Suarez-Almazor, Maria E. ;

Wang, Yinghong ;

Weber, Jeffrey S. ;

Wolchok, Jedd D. ;

Thompson, John A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+

[8] Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population [J].

Brzezianska, Ewa ;

Karbownik, Malgorzata ;

Migdalska-Sek, Monika ;

Pastuszak-Lewandoska, Dorota ;

Wloch, Jan ;

Lewinski, Andrzej .

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2006, 599 (1-2) :26-35

[9]

Ciccolini Kathryn, 2017, J Adv Pract Oncol, V8, P138

[10] Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors [J].

Cramer P. ;

Bresalier R.S. .

Current Gastroenterology Reports, 2017, 19 (1)

← 1 2 3 4 →